AKR1B10 and colonic neoplasm: This is the first comprehensive computational-based study that may lead to the findings and discovery of potent and selective inhibitors of either human aldose reductase (AKR1B1) or human small intestine reductase (AKR1B10), suggesting these derivatives for further exploration at the molecular level as ideal candidates for colon cancer and other associated malignancies.